Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26528398 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-26528398 | DRUG | In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1. |
| Placebo | DRUG | In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days. |
Inclusion Criteria: * Nonsmoker * Be in good health on the basis of physical examination, medical history, and electrocardiogram (ECG) * Must have good exercise tolerance * Have a body mass index of 18-29 kg/m2, inclusive, and body weight between 60 and 85 kg, inclusive * Have a history of consiste...
JNJ-26528398 is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, specifically in a completed trial that evaluated its safety, tolerability, and pharmacodynamic activity.
JNJ-26528398 is being studied for use in healthy participants. The completed Phase 1 trial assessed its safety, tolerability, and pharmacodynamic activity in healthy male participants. Its intended therapeutic use has not been specified beyond this initial healthy volunteer study.
JNJ-26528398 is developed by Johnson & Johnson, a company traded under the ticker JNJ. The drug is an investigational small molecule currently in Phase 1 clinical development.
JNJ-26528398 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a placebo-controlled, double-blind, randomized study in healthy male participants. The drug is investigational and has not been approved.
JNJ-26528398 has been studied in one completed clinical trial, NCT01520142, titled "Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants." This Phase 1 trial enrolled 19 healthy male participants in Belgium and was placebo-controlled and double-blind.